Your browser doesn't support javascript.
loading
Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection.
Holder, Kayla A; Ings, Danielle P; Harnum, Debbie O A; Russell, Rodney S; Grant, Michael D.
Afiliação
  • Holder KA; Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada. kayla.holder@mun.ca.
  • Ings DP; Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
  • Harnum DOA; Eastern Health Regional Health Authority, St. John's, NL, Canada.
  • Russell RS; Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
  • Grant MD; Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada. mgrant@mun.ca.
NPJ Vaccines ; 7(1): 122, 2022 Oct 21.
Article em En | MEDLINE | ID: mdl-36271095
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article